Table 6.
Ratio between duration of therapy or height (both evaluated as surrogate endpoints of efficacy) and number of side effects.
Leuprolide | Triptorelin | p-value | |
---|---|---|---|
Ratio | |||
Duration of treatment/N side effects; [median (Q1–Q3)] | 563 (411–836) | 730 (395–914) | 0.549 |
Height at the end of treatment (cm)/N side effects; [median (Q1–Q3)] | 103.8 (46.5−147.2) | 140.2 (133.6–149.7) | 0.374 |